Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE)
CUSIP: 22978P106
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Shares outstanding
- 43,411,663
- Total 13F shares
- 13,807,875
- Share change
- -2,579,924
- Total reported value
- $17,121,019
- Put/Call ratio
- 20%
- Price per share
- $1.24
- Number of holders
- 72
- Value change
- -$3,730,383
- Number of buys
- 33
- Number of sells
- 42
Quarterly Holders Quick Answers
What is CUSIP 22978P106?
CUSIP 22978P106 identifies CUE - Cue Biopharma, Inc. - Common Stock, $0.001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 22978P106:
Top shareholders of CUE - Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Bleichroeder LP |
13F
|
Company |
6.3%
|
2,755,028
|
$5,207,003 | — | 31 Mar 2024 | |
| Slate Path Capital LP |
13F
|
Company |
5.5%
|
2,402,455
|
$4,540,640 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.3%
|
2,283,362
|
$4,315,554 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
5.2%
|
2,244,103
|
$4,241,354 | — | 31 Mar 2024 | |
| Michael J. Fox |
3/4/5
|
Director |
—
mixed-class rows
|
1,148,800
mixed-class rows
|
$3,036,000 | — | 05 Jun 2024 | |
| Cameron Gray |
3/4/5
|
Director |
—
class O/S missing
|
687,049
|
$1,896,255 | — | 14 Jun 2022 | |
| Mark E. Strome |
13D/G
|
— |
5%
|
2,166,242
|
$1,862,968 | $0 | 14 Nov 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.9%
|
838,531
|
$1,585,043 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
1.8%
|
759,795
|
$1,436,013 | — | 31 Mar 2024 | |
| Robertson Stephens Wealth Management, LLC |
13F
|
Company |
1.1%
|
478,500
|
$904,365 | — | 31 Mar 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.99%
|
431,308
|
$815,172 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.84%
|
365,182
|
$690,195 | — | 31 Mar 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.83%
|
362,090
|
$684,350 | — | 31 Mar 2024 | |
| Monaco Asset Management SAM |
13F
|
Company |
0.77%
|
334,742
|
$632,662 | — | 31 Mar 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.63%
|
274,033
|
$518,000 | — | 31 Mar 2024 | |
| ADVISORY RESEARCH INC |
13F
|
Company |
0.59%
|
257,225
|
$486,155 | — | 31 Mar 2024 | |
| Sigma Planning Corp |
13F
|
Company |
0.59%
|
256,005
|
$483,849 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.56%
|
243,616
|
$460,434 | — | 31 Mar 2024 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.48%
|
209,100
|
$395,000 | — | 31 Mar 2024 | |
| Anish Suri |
3/4/5
|
PRESIDENT AND CSO |
—
mixed-class rows
|
285,638
mixed-class rows
|
$374,361 | — | 05 Jun 2024 | |
| STIFEL FINANCIAL CORP |
13F
|
Company |
0.44%
|
192,592
|
$364,001 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.35%
|
149,876
|
$283,266 | — | 31 Mar 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.34%
|
146,326
|
$276,556 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.34%
|
146,236
|
$276,386 | — | 31 Mar 2024 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.27%
|
116,152
|
$219,527 | — | 31 Mar 2024 | |
| Good Life Advisors, LLC |
13F
|
Company |
0.23%
|
100,000
|
$189,000 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0.21%
|
92,967
|
$175,707 | — | 31 Mar 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.21%
|
92,207
|
$174,270 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.21%
|
91,531
|
$172,994 | — | 31 Mar 2024 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.18%
|
77,500
|
$147,000 | — | 31 Mar 2024 | |
| CORNERCAP INVESTMENT COUNSEL INC |
13F
|
Company |
0.13%
|
57,888
|
$109,408 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.11%
|
45,638
|
$86,255 | — | 31 Mar 2024 | |
| Wedmont Private Capital |
13F
|
Company |
0.09%
|
40,000
|
$76,000 | — | 31 Mar 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.08%
|
33,655
|
$63,608 | — | 31 Mar 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.08%
|
32,597
|
$61,601 | — | 31 Mar 2024 | |
| Baker Avenue Asset Management, LP |
13F
|
Company |
0.07%
|
32,378
|
$61,194 | — | 31 Mar 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.07%
|
31,404
|
$59,353 | — | 31 Mar 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.07%
|
30,888
|
$58,379 | — | 31 Mar 2024 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.07%
|
29,801
|
$56,324 | — | 31 Mar 2024 | |
| OCCUDO QUANTITATIVE STRATEGIES LP |
13F
|
Company |
0.07%
|
29,076
|
$54,954 | — | 31 Mar 2024 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
0.06%
|
26,692
|
$50,448 | — | 31 Mar 2024 | |
| Navalign, LLC |
13F
|
Company |
0.06%
|
25,000
|
$47,250 | — | 31 Mar 2024 | |
| Cambridge Investment Research Advisors, Inc. |
13F
|
Company |
0.05%
|
22,200
|
$42,000 | — | 31 Mar 2024 | |
| Carlson Capital, L.P. |
13F
|
Company |
0.05%
|
20,000
|
$37,800 | — | 31 Mar 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.05%
|
19,974
|
$37,751 | — | 31 Mar 2024 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.04%
|
17,954
|
$33,933 | — | 31 Mar 2024 | |
| AMERICAN INTERNATIONAL GROUP, INC. |
13F
|
Company |
0.04%
|
17,735
|
$33,519 | — | 31 Mar 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.04%
|
15,426
|
$29,156 | — | 31 Mar 2024 | |
| Invesco Ltd. |
13F
|
Company |
0.04%
|
15,207
|
$28,741 | — | 31 Mar 2024 | |
| VOYA INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.03%
|
13,439
|
$25,400 | — | 31 Mar 2024 |
Institutional Holders of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) as of Q2 2024
As of 30 Jun 2024,
Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) was held by
72 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
13,807,875 shares.
The largest 10 holders included
Bleichroeder LP, Slate Path Capital LP, VANGUARD GROUP INC, BlackRock Inc., MILLENNIUM MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, Robertson Stephens Wealth Management, LLC, NORTHERN TRUST CORP, Good Life Advisors, LLC, and GSA CAPITAL PARTNERS LLP.
This page lists
72
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
74
Q2 2024 holders
72
Holder diff
-2
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.